Cyclobenzaprine: Comprehensive Drug Monograph

Pharmacokinetic Profile

Half-Life

IR: 18 h (8–37 h); ER: ~32 h

Metabolism

Hepatic (CYP3A4, CYP1A2, CYP2D6)

Protein Binding

93%

Bioavailability

33–55% (oral)

Volume of Distribution

~146 L

Clinical Information

Drug Class

Skeletal Muscle Relaxant (centrally acting, tricyclic)

Available Doses

IR: 5 mg, 7.5 mg, 10 mg; ER: 15 mg, 30 mg; SL: 2.8 mg

Route

Oral, Sublingual

Renal Adjustment

Not required

Hepatic Adjustment

IR: Start 5 mg; ER: Not recommended; Avoid in moderate-severe

Pregnancy

No adequate human data; use only if clearly needed

Lactation

Caution; limited data suggest low transfer into human milk

Schedule / Legal Status

Rx only (not a controlled substance)

Generic Available

Yes (IR and ER)

Cyclobenzaprine Indications

Indication	Approved Population	Therapy Type	Status
Muscle spasm associated with acute, painful musculoskeletal conditions	Adults and adolescents ≥15 years	Adjunct to rest and physical therapy	FDA Approved
Fibromyalgia (sublingual formulation only — Tonmya)	Adults ≥18 years	Monotherapy (bedtime dosing)	FDA Approved (Aug 2025)

Cyclobenzaprine is the most widely studied centrally acting muscle relaxant. For acute musculoskeletal spasm, it is intended for short-term use (2–3 weeks) only, as clinical trials have not demonstrated benefit beyond this period and because most acute musculoskeletal conditions are self-limited. It is ineffective for spasticity arising from central nervous system disorders such as cerebral palsy or spinal cord injury. In August 2025, the FDA approved Tonmya (cyclobenzaprine HCl sublingual tablets) for fibromyalgia in adults, making it the first new treatment approved for this condition in over 15 years.

Off-Label Uses

Low-dose for fibromyalgia-related sleep disturbance (oral IR) — Low-dose cyclobenzaprine (5–10 mg at bedtime) has been used off-label for fibromyalgia-associated sleep disruption. Several randomized trials demonstrate modest benefit for sleep quality and pain. Evidence quality: Moderate. Note that the approved sublingual formulation (Tonmya) is now the preferred route for this indication.

Temporomandibular joint disorder (TMD) — Some clinicians prescribe cyclobenzaprine for jaw muscle spasm and myofascial pain related to TMD. Evidence is limited to small trials and case series. Evidence quality: Low.

Dose

Cyclobenzaprine Dosing

Adult Dosing — By Clinical Scenario

Clinical Scenario	Starting Dose	Maintenance Dose	Maximum Dose	Notes
Acute musculoskeletal spasm — standard therapy (IR)	5 mg TID	5–10 mg TID	30 mg/day	Limit to 2–3 weeks; reassess if no improvement Onset within 1 h; some clinicians dose at bedtime only if sedation is problematic
Acute musculoskeletal spasm — once-daily dosing (ER)	15 mg once daily	15–30 mg once daily	30 mg/day	Take at approximately the same time each day Swallow capsule whole; may sprinkle on applesauce if unable to swallow
Fibromyalgia — sublingual (Tonmya)	2.8 mg SL at bedtime	5.6 mg SL at bedtime	5.6 mg/day	2.8 mg for first 14 days, then increase to 5.6 mg (two 2.8 mg tablets) Place under tongue at bedtime; do not chew or swallow tablets
Elderly patient — acute spasm (IR only)	5 mg once daily at bedtime	5 mg TID	15 mg/day	Titrate slowly; higher risk of confusion, falls, and anticholinergic effects ER formulation (Amrix) is not recommended in the elderly; Tonmya not studied in ≥65 years
Hepatic impairment — mild (IR only)	5 mg once daily	5 mg TID	15 mg/day	AUC approximately doubled in mild hepatic impairment Avoid IR in moderate-to-severe impairment; ER not recommended at any level of hepatic impairment
Fibromyalgia — mild hepatic impairment or geriatric (SL)	2.8 mg SL at bedtime	2.8 mg SL at bedtime	2.8 mg/day	Do not escalate to 5.6 mg in these populations (Tonmya PI)

Clinical Pearl: Duration of Therapy

For acute musculoskeletal spasm, cyclobenzaprine should be limited to 2–3 weeks. Clinical trials have not demonstrated continued benefit beyond this timeframe, and the underlying conditions are typically self-limited. In contrast, the sublingual formulation for fibromyalgia (Tonmya) is intended for chronic use, with clinical trials evaluating safety over 12 months. These are fundamentally different treatment paradigms despite sharing the same active molecule.

Pharmacology

Mechanism of Action

Cyclobenzaprine is structurally related to the tricyclic antidepressants amitriptyline and imipramine, differing from amitriptyline by only a single double bond in the central ring. It acts primarily within the central nervous system at the brainstem level, rather than at the spinal cord or neuromuscular junction, to reduce tonic somatic motor activity. The net pharmacological effect is a reduction in muscle hyperactivity through modulation of both gamma and alpha motor neuron systems. Cyclobenzaprine demonstrates functional antagonism at 5-HT_2A serotonergic, alpha₁-adrenergic, H₁-histaminergic, and M₁-muscarinic receptors. Its serotonin receptor antagonism and influence on descending serotonergic pathways are thought to underlie its efficacy in fibromyalgia, where it targets nonrestorative sleep architecture and central pain processing.

ADME Profile

Parameter	Value	Clinical Implication
Absorption	Oral bioavailability 33–55%; T_max ~4 h (IR), 7–8 h (ER); food increases AUC	Variable absorption contributes to interpatient variability in response; ER capsule provides sustained levels over 24 h
Distribution	V_d ~146 L; 93% protein-bound (primarily alpha₁-acid glycoprotein)	Extensive tissue distribution; binding to alpha₁-acid glycoprotein (an acute-phase reactant) means protein binding may increase during inflammation
Metabolism	Hepatic via CYP3A4 and CYP1A2 (major), CYP2D6 (minor); N-demethylation to norcyclobenzaprine; glucuronidation via UGT1A4/2B10; enterohepatic circulation	CYP3A4 and CYP1A2 inhibitors may increase exposure; sublingual route bypasses first-pass metabolism, reducing norcyclobenzaprine formation
Elimination	t_1/2 18 h (IR, range 8–37 h), ~32–35 h (ER); clearance 0.7 L/min; primarily renal as glucuronide conjugates	Long half-life causes accumulation at steady state (~4-fold with TID dosing); substantially prolonged in elderly (AUC ~1.7-fold higher) and hepatic impairment (AUC ~2-fold higher)

Side Effects

≥10% Very Common

Adverse Effect	Incidence	Clinical Note
Drowsiness / somnolence	29% (IR 5 mg); 38% (IR 10 mg)	Most common reason for discontinuation; dose-dependent; placebo rate ~10%; ER shows lower rate (~2% at 30 mg in controlled trials) (FDA PI)
Dry mouth	21% (IR 5 mg); 32% (IR 10 mg); 14% (ER 30 mg); 6% (ER 15 mg)	Anticholinergic effect; dose-dependent across all formulations; oral hygiene counselling important; risk of dental caries with prolonged use
Dizziness	11% (IR 10 mg clinical studies)	Dose-dependent; substantially lower at IR 5 mg (1–3%) and ER formulations (3–6%); contributes to fall risk in elderly

1–10% Common

Adverse Effect	Incidence	Clinical Note
Fatigue	6% (IR 5 & 10 mg); 3% (ER)	Usually improves within the first week; may be less pronounced with ER formulation
Headache	5% (IR)	Comparable to placebo rate (8%) in controlled trials; not clearly drug-related
Constipation	1–3% (IR); 3% (ER 30 mg)	Anticholinergic mechanism; increase fibre and fluid intake
Nausea	1–3% (IR); 3% (ER)	Take with food if gastrointestinal upset occurs
Dyspepsia	1–3%	Usually mild and self-limited
Blurred vision	1–3%	Anticholinergic effect; warn patients about driving impairment
Unpleasant taste	1–3%	More common with IR formulation; transient

Tonmya-specific (sublingual): Oral hypoesthesia (23%), abnormal product taste (11%), oral paresthesia (7%), oral discomfort, oral pain, and aphthous ulcer were common local effects in the RELIEF and RESILIENT trials. These were transient and self-limited.

Serious Serious (Regardless of Frequency)

Adverse Effect	Estimated Frequency	Typical Onset	Required Action
Serotonin syndrome	Rare	Hours to days after initiation or dose increase, especially with concomitant serotonergic drugs	Discontinue cyclobenzaprine and all serotonergic agents immediately; supportive care; cyproheptadine may be considered
Cardiac arrhythmias (tachycardia, conduction disturbances, QRS prolongation)	Rare (<1%)	Any time during therapy; higher risk with overdose or in patients with pre-existing cardiac disease	ECG monitoring; discontinue if QRS widening; cardiology consultation; sodium bicarbonate for significant QRS prolongation
Anaphylaxis / angioedema	Very rare	Any time, typically early in therapy	Permanent discontinuation; emergency treatment with epinephrine
Seizures	Very rare	Primarily in overdose; may occur at therapeutic doses with predisposing factors	Discontinue; benzodiazepines for acute seizure management; neurology referral
Hepatitis / cholestasis	Very rare (case reports)	Weeks to months	Discontinue; monitor liver function tests; hepatology referral if LFTs > 3x ULN
Neuroleptic malignant syndrome	Very rare (overdose)	Primarily reported in overdose settings	Emergency care; discontinue all causative agents; dantrolene and supportive measures

Discontinuation Discontinuation Data

IR Clinical Trials (10 mg TID)

~7–9%

Top reasons: Drowsiness, dry mouth, dizziness, and other CNS effects

ER Clinical Trials (30 mg QD)

~5–8%

Top reasons: Dry mouth, dizziness, fatigue; lower overall discontinuation compared to IR in surveillance data

Reason for Discontinuation	Incidence	Context
Drowsiness / somnolence	Most common	Dose-related; 5 mg dose associated with significantly lower sedation vs 10 mg
Dry mouth	Common	More frequent at higher doses; often tolerable with oral care
Dizziness	Less common	Usually dose-related; resolves with dose reduction or discontinuation

Managing Sedation — The Most Common Limiting Side Effect

Drowsiness affects up to 38% of patients at the 10 mg TID dose but is substantially lower at 5 mg TID (29%) and with the ER formulation. Strategies include starting at the lowest effective dose, administering the largest portion at bedtime, and using the ER formulation for patients who need once-daily convenience with a smoother pharmacokinetic profile. Advise patients that sedation typically improves within the first 3–4 days of treatment. If somnolence remains intolerable, the 5 mg dose three times daily is often sufficient for clinical benefit.

Int

Drug Interactions

Cyclobenzaprine is metabolized primarily by CYP3A4 and CYP1A2, with minor contribution from CYP2D6. Its structural similarity to tricyclic antidepressants means it shares many of the same interaction liabilities, particularly with serotonergic drugs, MAO inhibitors, and CNS depressants. The sublingual formulation bypasses first-pass metabolism but retains systemic interaction potential.

Major MAO Inhibitors (selegiline, phenelzine, tranylcypromine, isocarboxazid, linezolid)

MechanismImpaired monoamine degradation combined with reuptake inhibition

EffectHyperpyretic crisis, seizures, and death have been reported

ManagementAbsolute contraindication: do not use cyclobenzaprine during or within 14 days of MAOI discontinuation

FDA PI

Major Serotonergic Agents (SSRIs, SNRIs, triptans, tramadol, meperidine, St John’s Wort)

MechanismAdditive serotonergic activity via reuptake inhibition and receptor effects

EffectRisk of serotonin syndrome (altered mental status, autonomic instability, neuromuscular excitability)

ManagementIf co-administration unavoidable, use lowest doses with close monitoring; educate patient on serotonin syndrome symptoms

FDA PI

Major Alcohol & CNS Depressants (benzodiazepines, opioids, barbiturates, sedating antihistamines)

MechanismAdditive central nervous system depression

EffectEnhanced sedation, respiratory depression, impaired psychomotor function

ManagementCounsel patients to avoid alcohol; use lowest effective doses of concurrent CNS depressants; monitor for excessive sedation

FDA PI

Moderate Strong CYP1A2 Inhibitors (fluvoxamine, ciprofloxacin)

MechanismCYP1A2 is a primary metabolic pathway for cyclobenzaprine N-demethylation

EffectIncreased cyclobenzaprine plasma concentrations; enhanced side effects

ManagementConsider starting at 5 mg dose; monitor for excessive sedation and anticholinergic effects

Lexicomp

Moderate Anticholinergic Agents (oxybutynin, benztropine, first-generation antihistamines)

MechanismAdditive muscarinic receptor blockade

EffectIncreased risk of urinary retention, constipation, ileus, confusion, and heat intolerance

ManagementAssess anticholinergic burden; avoid combination in elderly patients; monitor bowel and bladder function

FDA PI

Moderate Guanethidine & Similarly Acting Antihypertensives

MechanismTricyclic structure blocks neuronal uptake of guanethidine

EffectDecreased antihypertensive efficacy

ManagementMonitor blood pressure; consider alternative antihypertensive class

FDA PI

Moderate Tramadol

MechanismAdditive serotonergic effect; tricyclic compounds may lower seizure threshold

EffectIncreased risk of seizures and serotonin syndrome

ManagementAvoid combination when possible; if used, monitor closely for both seizure activity and serotonin syndrome symptoms

FDA PI

Minor NSAIDs (aspirin, naproxen, ibuprofen)

MechanismNo significant pharmacokinetic interaction

EffectCombination with naproxen may increase drowsiness; no change in plasma levels of either drug

ManagementSafe to co-administer; warn about additive drowsiness if applicable

FDA PI

Mon

Monitoring

Symptom Response At 1–2 weeks, then at 3 weeks
Routine Assess pain relief, muscle spasm resolution, and functional improvement. If no benefit after 2–3 weeks, discontinue (for acute musculoskeletal indication). For fibromyalgia (Tonmya), assess at weeks 2, 4, and 14 per clinical trial design.
CNS Effects Each visit
Routine Monitor for excessive drowsiness, dizziness, confusion, and cognitive impairment, especially in elderly patients. Assess ability to drive and operate machinery safely.
Hepatic Function Baseline (if risk factors); as clinically indicated
Trigger-based Obtain baseline liver function tests in patients with known hepatic disease. Repeat if symptoms of hepatotoxicity develop (jaundice, dark urine, unexplained abdominal pain). Drug is not recommended in moderate-to-severe hepatic impairment.
Cardiac Status Baseline ECG if cardiac risk factors
Trigger-based Consider baseline ECG in patients with pre-existing cardiac conduction abnormalities or those on other QT-prolonging medications. Monitor for palpitations, tachycardia, or syncope during therapy.
Anticholinergic Burden Baseline and periodically
Routine Assess for urinary retention, constipation, dry mouth, blurred vision, and cognitive effects. Particularly important when combined with other anticholinergic medications; use anticholinergic burden scoring tools in elderly.
Serotonin Syndrome Signs After initiation or dose change with concurrent serotonergic drugs
Trigger-based Monitor for agitation, hyperthermia, diaphoresis, tachycardia, hyperreflexia, clonus, and altered mental status if cyclobenzaprine is co-prescribed with SSRIs, SNRIs, triptans, or tramadol.

Contraindications & Cautions

Absolute Contraindications

Hypersensitivity to cyclobenzaprine or any component of the formulation
Concomitant MAO inhibitor use or use within 14 days of MAOI discontinuation — risk of hyperpyretic crisis, seizures, and death
Acute recovery phase of myocardial infarction
Cardiac arrhythmias, heart block, or conduction disturbances
Congestive heart failure
Hyperthyroidism

Relative Contraindications (Specialist Input Recommended)

Moderate-to-severe hepatic impairment — drug is not recommended due to substantially increased plasma concentrations and lack of safety data
Elderly patients (≥65 years) — Beers Criteria lists cyclobenzaprine as potentially inappropriate; ER formulation is not recommended; increased risk of falls, confusion, delirium, and anticholinergic effects
Concurrent use of multiple serotonergic agents — risk-benefit assessment required due to serotonin syndrome risk; consider alternative muscle relaxant

Use with Caution

Mild hepatic impairment — start IR at 5 mg with slow titration; ER not recommended
History of urinary retention or angle-closure glaucoma — anticholinergic properties may worsen these conditions
Increased intraocular pressure — monitor if pre-existing ocular hypertension
Patients taking anticholinergic medications — additive anticholinergic burden
Patients operating heavy machinery or driving — impaired mental and physical abilities, especially early in therapy

FDA Class-Wide Safety Advisory Serotonin Syndrome Risk with Serotonergic Drugs

Cyclobenzaprine, due to its structural and pharmacological similarity to tricyclic antidepressants, carries a risk of serotonin syndrome when used with other serotonergic agents. Cases have been reported when combined with SSRIs, SNRIs, triptans, and MAO inhibitors. Clinicians should be vigilant for the triad of altered mental status, autonomic instability, and neuromuscular excitability. The combination with MAO inhibitors is an absolute contraindication due to reports of fatal hyperpyretic crises.

Patient Counselling

Purpose of Therapy

Cyclobenzaprine is a muscle relaxant used alongside rest and physical therapy to relieve muscle spasm and the associated pain, tenderness, and limited movement that accompany acute musculoskeletal injuries. For the sublingual formulation (Tonmya), the medication is used specifically for fibromyalgia, targeting chronic pain and sleep disturbance. It is important to explain that for acute muscle spasm, the medication is intended for short-term use (2–3 weeks) only, whereas the fibromyalgia indication involves ongoing treatment.

How to Take

Immediate-release tablets: Swallow whole with water. Take at evenly spaced intervals throughout the day, or as directed. If drowsiness is significant, the prescriber may adjust timing so the larger portion is taken at bedtime. Extended-release capsules: Swallow whole at approximately the same time each day. If unable to swallow the capsule, it may be opened and the contents sprinkled on a tablespoon of applesauce and swallowed immediately without chewing. Sublingual tablets (Tonmya): Place under the tongue at bedtime and allow to dissolve completely. Do not chew or swallow the tablet. Do not eat or drink for at least 10 minutes after administration.

Drowsiness & Dizziness

Tell patient Drowsiness is the most common side effect and affects about 1 in 3 patients. It usually lessens after the first few days. Avoid driving, operating heavy machinery, or performing activities requiring full alertness until you know how cyclobenzaprine affects you. Taking the medication at bedtime or using the extended-release formulation may reduce daytime sedation.

Call prescriber If drowsiness is so severe that it interferes with daily activities after the first week, or if you experience confusion, hallucinations, or difficulty with coordination.

Alcohol & Other Sedating Substances

Tell patient Cyclobenzaprine intensifies the effects of alcohol, sleeping pills, and other sedating medications. Even small amounts of alcohol can cause marked drowsiness when taken with this medication. Avoid alcohol entirely during treatment.

Call prescriber If you accidentally combined cyclobenzaprine with alcohol or sedatives and experience severe drowsiness, difficulty breathing, or loss of consciousness.

Dry Mouth

Tell patient Dry mouth is very common (up to 32% at higher doses). Sip water frequently, use sugar-free gum or candies to stimulate saliva, and maintain good oral hygiene to prevent dental problems. Consider saliva substitutes if troublesome.

Call prescriber If dry mouth is accompanied by difficulty swallowing, persistent mouth sores, or dental complications despite management strategies.

Duration of Therapy

Tell patient For muscle spasm, cyclobenzaprine is intended for 2–3 weeks only. Do not continue taking it beyond this period without your prescriber’s specific instruction. There is no evidence of benefit for acute musculoskeletal conditions beyond 3 weeks, and the underlying condition is usually self-limited.

Call prescriber If symptoms have not improved after 2–3 weeks of treatment, or if they worsen at any point.

Serotonin Syndrome Awareness

Tell patient If you are taking antidepressants (especially SSRIs or SNRIs), migraine medications (triptans), or certain pain medications (tramadol), there is a small risk of a condition called serotonin syndrome. Know the warning signs: agitation, fast heartbeat, fever, sweating, muscle stiffness or twitching, confusion, and diarrhoea.

Call prescriber Seek immediate medical attention if you develop any combination of these symptoms, especially fever with muscle rigidity, rapid heartbeat, and mental status changes.

Sublingual Administration (Tonmya)

Tell patient Place the sublingual tablet under your tongue at bedtime. Let it dissolve completely without chewing or swallowing. Do not eat or drink for at least 10 minutes. Temporary numbness, tingling, or an unusual taste in the mouth are common local effects and are not harmful. Take at the same time each night.

Call prescriber If you develop persistent mouth sores (aphthous ulcers) that do not heal, or if numbness or tingling worsens or does not resolve between doses.

Ref

Sources

Regulatory (PI / SmPC)

Flexeril (cyclobenzaprine hydrochloride) tablets. Full Prescribing Information. McNeil Consumer & Specialty Pharmaceuticals. FDA Label (NDA 17-821/S-045) Primary source for IR formulation dosing, adverse reactions with incidence rates (5 mg vs 10 mg), contraindications, and pharmacokinetic parameters.
Amrix (cyclobenzaprine hydrochloride extended-release capsules). Full Prescribing Information. Teva Pharmaceuticals. Revised May 2024. DailyMed Source for ER formulation dosing (15 mg and 30 mg), adverse reaction rates from Phase 3 trials, and hepatic/elderly precautions.
Tonmya (cyclobenzaprine hydrochloride sublingual tablets). Full Prescribing Information. Tonix Pharmaceuticals. August 2025. Tonix Pharmaceuticals Source for sublingual formulation dosing for fibromyalgia, local adverse effects (oral hypoesthesia, paresthesia), and embryo-fetal toxicity warnings.

Key Clinical Trials

Darwish M, Hellriegel ET. Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers. Clin Ther. 2011;33(6):746-753. doi:10.1016/j.clinthera.2011.05.043 Characterised ER steady-state PK: T_max 7 h, t_1/2 34.8 h; source for ER pharmacokinetic data cited in the ADME table.
Lederman S, et al. Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine (RELIEF trial). Arthritis Care Res. 2023. NCT04172831. Phase 3 RELIEF trial (n=503) demonstrating significant reduction in daily pain intensity scores vs placebo at 14 weeks with Tonmya.
Lederman S, et al. Efficacy and safety of TNX-102 SL in patients with fibromyalgia (RESILIENT trial). Pain Med. 2025. NCT05273749. Phase 3 RESILIENT trial (n=457) confirming pain reduction with sublingual cyclobenzaprine (mean change -1.8 vs -1.2 placebo, P<.001).

Guidelines

Chou R, et al. Nonpharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. Ann Intern Med. 2017;166(7):493-505. doi:10.7326/M16-2459 ACP guideline recommending muscle relaxants including cyclobenzaprine as a second-line option for acute low back pain when NSAIDs are insufficient.
2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 Updated AGS Beers Criteria. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 Lists cyclobenzaprine as potentially inappropriate in older adults due to anticholinergic effects, sedation, and fall risk.

Mechanistic / Basic Science

Kobayashi H, Hasegawa Y, Ono H. Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol. 1996;311(1):29-35. doi:10.1016/0014-2999(96)00402-5 Demonstrated cyclobenzaprine’s action on descending serotonergic systems, informing the mechanistic rationale for its use in fibromyalgia.
Moldofsky H, et al. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a randomized, double-blind, placebo-controlled study. J Rheumatol. 2011;38(12):2653-2663. doi:10.3899/jrheum.110194 Early proof-of-concept study for low-dose sublingual cyclobenzaprine in fibromyalgia, demonstrating improved sleep physiology.

Pharmacokinetics / Special Populations

Brioschi MB, et al. Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets. Biomed Res Int. 2013;2013:281392. doi:10.1155/2013/281392 Comprehensive PK study reporting V_d ~146 L, multicompartment elimination, and Tmax ~4.5 h for IR formulation.
Khan I, Kahwaji CI. Cyclobenzaprine. In: StatPearls. Treasure Island (FL): StatPearls Publishing; Updated August 2023. NCBI Bookshelf Comprehensive clinical review covering pharmacology, PK parameters (protein binding 93%, CYP involvement), dosing, and toxicology management.
Huang Z, Ung T. Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics. Curr Drug Metab. 2013;14(2):226-238. doi:10.2174/1389200211314020011 Explains the clinical significance of cyclobenzaprine’s high binding to alpha₁-acid glycoprotein and how inflammation may alter drug availability.